SDZ RAD is a new, orally active rapamycin-derivative that is immunosuppressive and that efficiently prevents graft rejection in rat models of allotransplantation. SDZ RAD has been selected for development for use in combination with cyclosporine A to prevent acute and chronic rejection after solid organ allotransplantation.